Frontiers in Bioscience-Landmark (Apr 2022)

CAR-T Cells Targeting Immune Checkpoint Pathway Players

  • Vita Golubovskaya

DOI
https://doi.org/10.31083/j.fbl2704121
Journal volume & issue
Vol. 27, no. 4
p. 121

Abstract

Read online

CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.

Keywords